RESUMEN
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver cancer. Although the etiology is likely multifactorial, genes involved in regulating lipid metabolism are enriched in human NAFLD genome-wide association studies (GWAS), pointing to dysregulated lipid metabolism as a major pathogenic factor. Glycerol-3-phosphate acyltransferase 1 (GPAT1), encoded by GPAM, converts acyl-CoAs and glycerol-3-phosphate into lysophosphatidic acid and has been shown to regulate lipid accumulation in the liver. However, its role in mediating the progression from NAFLD to NASH has not been explored. METHODS: GPAT1-deficient mice were generated and challenged with diets inducing hepatic steatosis and NASH. Effects of GPAT1 deficiency on lipid and systemic metabolic end points were evaluated. RESULTS: Ablating GPAT1 globally or specifically in mouse hepatocytes reduced hepatic steatosis in the context of diet-induced or genetic obesity. Interestingly, blunting of progression from NAFLD to NASH in global GPAT1 knockout (KO) mice was model dependent. GPAT1 KO mice were protected from choline deficient, amino acid defined high-fat diet-induced NASH development, but not from the high fat, high carbohydrate, and high cholesterol diet-induced NASH. CONCLUSIONS: Our preclinical data support the notion that lipid metabolism pathways regulated by GPAT1 in hepatocytes play an essential role in NASH progression, albeit in a model-dependent manner.
Asunto(s)
Enfermedad del Hígado Graso no Alcohólico , Ratones , Animales , Humanos , Enfermedad del Hígado Graso no Alcohólico/patología , Estudio de Asociación del Genoma Completo , Glicerol , Dieta Alta en Grasa/efectos adversos , Ratones Noqueados , Fosfatos , LípidosRESUMEN
BACKGROUND: Endothelium-dependent flow mediated dilation (FMD) and pulse-wave velocity (PWV), are used as measures of vascular health and predictors of cardiovascular risk in clinical studies, and both are age-dependent. Numbers of circulating endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are also associated with cardiovascular risk, but independent of age in humans. The use of these measurements for pre-clinical assessment of drug cardiovascular safety and efficacy in non-human primates (NHPs) may promote the translation of drug-induced effects on vascular function to clinic outcomes. However, in NHPs, the age effects on the non-invasive measurements of FMD and PWV and the relationship of EMPs/EPCs with FMD are unknown. METHODS: A non-invasive, clinically-relevant approach to assess FMD and PWV was used to examine their relationship with age and with EMPs/EPCs in NHPs. The effects on FMD of nicotine and rosiglitazone were evaluated in senescent primates in an effort to validate our FMD method for pre-clinical assessment of vascular function. RESULTS: FMD and PWV methods were established in a colony (n = 25) of metabolically healthy, cynomolgus monkeys ranging in age from 6 to 26 years. FMD, defined as the percent change, at 1 min of cuff release, from baseline vascular diameter (0.15 ± 0.03 cm), had a strong, negative correlation with age (r = -0.892, p < 0.0001), ranging from 6% to 33%. PWV positively correlated with age (r = 0.622, p < 0.002) in the same healthy monkeys. Nicotine and rosiglitazone, were evaluated in subsets of senescent primates (mean age 16.3 ± 1.5[SEM] years). Rosiglitazone significantly improved FMD (21.0 ± 1.6% vs. vehicle 16.3 ± 1.6%, p < 0.01) without changing baseline diameters, and coincided with a significant increase in circulating numbers of endothelial progenitor cells (CD45-CD31 + CD34 + VEGFR2+ 7.1 ± 1.3 vs. 4.8 ± 1.1 counts/µl) and a decrease in endothelial microparticles (CD45-CD42a-CD54+ 26.7 ± 11.1 vs. 62.2 ± 9.8 counts/µl)(p < 0.05). Conversely, FMD was significantly reduced with nicotine (8.7 ± 1.4% vs. vehicle 20.1 ± 2.2%, p < 0.05). CONCLUSIONS: Adult NHPs demonstrate the characteristic linear relationship between age and vascular function using the non-invasive clinically-related measurements of FMD and PWV. However, numbers of circulating EMPs and EPCs did not correlate with age. Endothelial function assessed with FMD, together with EMPs/EPCs assessment, may serve as a novel approach for translational research and therapeutic discovery. Age should be considered in the study design or data analyses when FMD or PWV is used in NHPs.
Asunto(s)
Células Endoteliales/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/patología , Nicotina/farmacología , Células Madre/efectos de los fármacos , Tiazolidinedionas/farmacología , Factores de Edad , Animales , Arteria Braquial/patología , Descubrimiento de Drogas , Células Endoteliales/citología , Femenino , Arteria Femoral/patología , Prueba de Tolerancia a la Glucosa , Lipopolisacáridos/metabolismo , Macaca fascicularis , Masculino , Rosiglitazona , Células Madre/citología , Investigación Biomédica TraslacionalRESUMEN
A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Piperidinas/uso terapéutico , Humanos , Modelos Moleculares , Piperidinas/químicaRESUMEN
BACKGROUND & AIMS: Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL) and modulates mitochondrial fatty acid oxidation. Increased hepatic DNL flux and reduced fatty acid oxidation are hypothesized to contribute to steatosis. Some proinflammatory cells also show increased dependency on DNL, suggesting that ACC may regulate aspects of the inflammatory response in NASH. PF-05221304 is an orally bioavailable, liver-directed ACC1/2 inhibitor. The present studies sought to evaluate the effects of PF-05221304 on NASH pathogenic factors in experimental model systems. METHODS: The effects of PF-05221304 on lipid metabolism, steatosis, inflammation, and fibrogenesis were investigated in both primary human-derived in vitro systems and in vivo rodent models. RESULTS: PF-05221304 inhibited DNL, stimulated fatty acid oxidation, and reduced triglyceride accumulation in primary human hepatocytes, and reduced DNL and steatosis in Western diet-fed rats in vivo, showing the potential to reduce hepatic lipid accumulation and potentially lipotoxicity. PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis. Consistent with these observations, PF-05221304 also reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical-induced liver injury model and the choline-deficient, high-fat-fed rat model. CONCLUSIONS: The liver-directed dual ACC1/ACC2 inhibitor directly improved multiple nonalcoholic fatty liver disease/NASH pathogenic factors including steatosis, inflammation, and fibrosis in both human-derived in vitro systems and rat models.
Asunto(s)
Acetil-CoA Carboxilasa/antagonistas & inhibidores , Inhibidores Enzimáticos/uso terapéutico , Hígado/efectos de los fármacos , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Acetil-CoA Carboxilasa/metabolismo , Animales , Humanos , Lipogénesis/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/patología , Ratas Sprague-DawleyRESUMEN
A promising area of novel anti-diabetic therapy involves identification of small molecule activators of the glucokinase enzyme to reduce blood glucose and normalize glucose stimulated insulin secretion. Herein, we report the identification and optimization of a series of 4-sulfonyl-2-pyridone activators. The activators were evaluated for in vitro biochemical activation and pharmacokinetic properties. As part of these efforts, a unique metabolic liability of the 4-sulfonyl-2-pyridone ring system was identified wherein this heterocycle readily undergoes conjugation with glutathione under non-enzymatic conditions.
Asunto(s)
Glucoquinasa/efectos de los fármacos , Hipoglucemiantes/farmacocinética , Piridonas/farmacocinética , Animales , Glucemia , Activación Enzimática/efectos de los fármacos , Glutatión/química , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/metabolismo , Microsomas Hepáticos/metabolismo , Piridonas/química , Piridonas/metabolismo , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
PURPOSE: Exercise is recommended in addition to pharmacotherapies for the management of type 2 diabetes, but metformin and exercise training may have non-additive or even inhibitory effects on exercise-induced improvements in glycemic control and exercise capacity. The objectives of this report were to determine if co-treatment with a sodium-glucose cotransporter-2 inhibitor and exercise could (1) further improve glycemic control when compared to either monotherapy and (2) not worsen exercise capacity when compared to exercise alone. METHODS: A rodent model of type 2 diabetes (30â¯mg/kg streptozotocin and high-fat feeding in male Sprague-Dawley rats) was used to assess 12â¯weeks of co-treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and exercise (EX; treadmill running) on glycemic control and exercise capacity. Animals were randomized to the following conditions (nâ¯=â¯7-10/group): vehicle (0.5% methyl cellulose) sedentary (VEH SED), VEH EX, canagliflozin (3â¯mgâ¯kg-1â¯d-1) SED (SGLT2i SED), or SGLT2i EX. RESULTS: Both EX and SGLT2i independently improved indices of glycemic control. The combination of SGLT2i and EX further improved glucose tolerance (glucose area under the curve 1109⯱â¯51 vs 1427⯱â¯82â¯mmol/â¯L 120â¯min-1 for SGLT2i EX vs. SGLT2i SED, respectively; pâ¯<â¯0.05) and insulin responses (insulin area under the curve 24,524⯱â¯4126 vs. 41,208⯱â¯2714â¯pmolâ¯L-1 120â¯min-1 for SGLT2i EX vs. VEH EX, respectively; pâ¯<â¯0.05) during an oral glucose tolerance test. Only the combination of SGLT2i EX lowered body weight compared to VEH SED (pâ¯<â¯0.01). SGLT2i caused several metabolic adaptations including increased ketone production and a greater reliance on fat as a source of energy during normal cage activity. Interestingly, animals that were given the SGLT2i and underwent exercise training (SGLT2i EX) had better submaximal exercise capacity than EX alone, as indicated by distance run prior to fatigue (882⯱â¯183 vs.433⯱â¯33â¯m for SGLT2i EX and VEH EX, respectively; pâ¯<â¯0.01), and this was accompanied by a greater reliance on fat as an energy source during exercise (pâ¯<â¯0.01). CONCLUSIONS: If these findings with the combination of SGLT2i and exercise translate to humans, they will have important clinical health implications.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/metabolismo , Tolerancia al Ejercicio/efectos de los fármacos , Condicionamiento Físico Animal/fisiología , Roedores/metabolismo , Inhibidores del Cotransportador de Sodio-Glucosa 2/farmacología , Transportador 2 de Sodio-Glucosa/metabolismo , Animales , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/metabolismo , Modelos Animales de Enfermedad , Tolerancia al Ejercicio/fisiología , Glucosa/metabolismo , Prueba de Tolerancia a la Glucosa/métodos , Insulina/metabolismo , Masculino , Metformina/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
PURPOSE: The purpose of this study was to describe the failure rates of maxillary expansion appliances (MEAs) and assess risk variables associated with failures and treatment time. METHODS: Retrospective chart reviews were performed on 436 primary or mixed dentition patients presenting with crossbite to a private practice between 1981-2005. Survival analysis was used to analyze and compare the types of MEAs with respect to the treatment time. The effect of demographic and clinical characteristics on appliance failure and treatment time was assessed using linear and logistic regression models. RESULTS: The average age at insertion of a MEA was 8 years, 4 months (+/-1.72 SD). Nineteen percent (n=84) of the MEAs failed, with a median treatment time for all appliances of 216 days (interquartile range=126 days). Cement loss (69%) was the most common type of failure. The likelihood of an appliance failing increased in children with a malocclusion other than Class I (adjusted odds ratio=1.91; 95% CI=1.16-3.14) and was nearly 4 times greater when a quad helix was used compare to the Haas appliance (adjusted odds ratio=3.60; 95% CI=1.92-6.75). The treatment time was significantly affected by the type of crossbite present and the occurrence of an appliance failure (P=.001). CONCLUSIONS: The use of a quad helix appliance and the presence of malocclusion other than Class I was significantly predictive of appliance failure. Treatment time was increased when MEAs failed and bilateral crossbite was present.
Asunto(s)
Maloclusión/terapia , Diseño de Aparato Ortodóncico , Aparatos Ortodóncicos/clasificación , Técnica de Expansión Palatina/instrumentación , Cementación , Niño , Femenino , Humanos , Modelos Logísticos , Masculino , Maloclusión/clasificación , Estudios Retrospectivos , Análisis de Supervivencia , Insuficiencia del TratamientoRESUMEN
Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. Until now, studies on KHK inhibition with small molecules have been limited due to the lack of viable in vivo pharmacological tools. Herein we report the discovery of 12, a selective KHK inhibitor with potency and properties suitable for evaluating KHK inhibition in rat models. Key structural features interacting with KHK were discovered through fragment-based screening and subsequent optimization using structure-based drug design, and parallel medicinal chemistry led to the identification of pyridine 12.
Asunto(s)
Diseño de Fármacos , Fructoquinasas/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Bibliotecas de Moléculas Pequeñas/química , Bibliotecas de Moléculas Pequeñas/farmacología , Animales , Cristalografía por Rayos X , Fructoquinasas/química , Fructoquinasas/metabolismo , Humanos , Masculino , Simulación del Acoplamiento Molecular , Piridinas/química , Piridinas/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Sorbitol dehydrogenase (hSDH) and aldose reductase form the polyol pathway that interconverts glucose and fructose. Redox changes from overproduction of the coenzyme NADH by SDH may play a role in diabetes-induced dysfunction in sensitive tissues, making SDH a therapeutic target for diabetic complications. We have purified and determined the crystal structures of human SDH alone, SDH with NAD(+), and SDH with NADH and an inhibitor that is competitive with fructose. hSDH is a tetramer of identical, catalytically active subunits. In the apo and NAD(+) complex, the catalytic zinc is coordinated by His69, Cys44, Glu70, and a water molecule. The inhibitor coordinates the zinc through an oxygen and a nitrogen atom with the concomitant dissociation of Glu70. The inhibitor forms hydrophobic interactions to NADH and likely sterically occludes substrate binding. The structure of the inhibitor complex provides a framework for developing more potent inhibitors of hSDH.
Asunto(s)
Cristalografía por Rayos X , L-Iditol 2-Deshidrogenasa/química , Sitios de Unión , Humanos , Cinética , L-Iditol 2-Deshidrogenasa/metabolismo , Funciones de Verosimilitud , Unión Proteica , Conformación ProteicaRESUMEN
Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess glucose flux through the polyol pathway that prevails under diabetic conditions has been a long-standing challenge. In response, we did high-throughput screening of our internal libraries of compounds and identified 6-phenylsulfonylpyridazin-2H-3-one, 8, which showed modest inhibition of AR, both in vitro and in vivo. Initial structure-activity relationships concentrated on phenyl substituents and led to 6-(2,4-dichlorophenylsulfonyl)-2H-pyridazin-3-one, 8l, which was more potent than 8, both in vitro and in vivo. Incorporation of extant literature findings with other aldose reductase inhibitors, including zopolrestat, resulted in the title inhibitor, 19m, which is one of the most potent and highly selective non-carboxylic acid, non-hydantoin inhibitors of AR yet described (IC50, 1 nM; ED90 vs sciatic nerve sorbitol and fructose, respectively, 0.8 and 4.0 mg/kg). In rats, its oral bioavailability is 98% and it has a favorable plasma t(1/2) (26 +/- 3 h).
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Aldehído Reductasa/química , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/síntesis química , Piridazinas/síntesis química , Sulfonas/síntesis química , Administración Oral , Animales , Disponibilidad Biológica , Células CACO-2 , Fructosa/metabolismo , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Cristalino/metabolismo , Masculino , Piridazinas/química , Piridazinas/farmacología , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/antagonistas & inhibidores , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Sorbitol/metabolismo , Relación Estructura-Actividad , Sulfonas/química , Sulfonas/farmacologíaRESUMEN
Optimization of a previously disclosed sorbitol dehydrogenase inhibitor (SDI, II) for potency and duration of action was achieved by replacing the metabolically labile N,N-dimethylsulfamoyl group with a variety of heterocycles. Specifically, this effort led to a series of novel, in vitro potent SDIs with longer serum half-lives and acceptable in vivo activity in acutely diabetic rats (e.g., 62, 67, and 69). However, the desired in vivo potency in chronically diabetic rats, ED(90) < or = 5 mg/kg/day, was achieved only through further modification of the piperazine linker. Several members of this family, including 86, showed better than the targeted potency with ED(90) values of 1-2 mg/kg/day. Compound 86 was further profiled and found to be a selective inhibitor of sorbitol dehydrogenase, with excellent pharmacodynamic/pharmacokinetic properties, demonstrating normalization of sciatic nerve fructose in a chronically diabetic rat model for approximately 17 h, when administered orally at a single dose of 2 mg/kg/day.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , L-Iditol 2-Deshidrogenasa/antagonistas & inhibidores , Piperazinas/síntesis química , Pirimidinas/síntesis química , Animales , Enfermedad Crónica , Diabetes Mellitus Experimental/metabolismo , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Fructosa/metabolismo , Masculino , Piperazinas/química , Piperazinas/farmacocinética , Piperazinas/farmacología , Pirimidinas/química , Pirimidinas/farmacocinética , Pirimidinas/farmacología , Ratas , Ratas Sprague-Dawley , Nervio Ciático/metabolismo , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 microg/kg) in normalizing elevated fructose levels in the sciatic nerve of chronically diabetic rats and sustained duration of action (>24 h). Furthermore, 16 shows attractive pharmaceutical properties, including good solubility in simulated human gastric fluid, excellent Caco-2 Papp, moderate lipophilicity, and metabolic stability for achieving good oral absorption and long duration of action.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , L-Iditol 2-Deshidrogenasa/antagonistas & inhibidores , Pirimidinas/síntesis química , Triazinas/síntesis química , Administración Oral , Animales , Células CACO-2 , Diabetes Mellitus/metabolismo , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Fructosa/metabolismo , Humanos , Pirimidinas/química , Pirimidinas/farmacología , Ratas , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Solubilidad , Estereoisomerismo , Relación Estructura-Actividad , Triazinas/química , Triazinas/farmacologíaRESUMEN
We report here on the discovery path that led to a structurally unprecedented non-hydantoin, non-carboxylic acid aldose reductase inhibitor, 24, which shows remarkably potent oral activity in normalizing elevated sorbitol levels and, more significantly, fructose levels in the sciatic nerve of chronically diabetic rats, with ED(90) values of 0.8 and 3 mpk, respectively. It is well absorbed in rats (oral bioavailability, 98%) and has a long plasma t(1/2) (26 +/- 3 h).
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Diabetes Mellitus Experimental/metabolismo , Inhibidores Enzimáticos/síntesis química , Hipoglucemiantes/síntesis química , Piridazinas/síntesis química , Sulfonas/síntesis química , Administración Oral , Aldehído Reductasa/química , Animales , Disponibilidad Biológica , Células CACO-2 , Técnicas Químicas Combinatorias , Cristalografía por Rayos X , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Fructosa/sangre , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Cristalino/efectos de los fármacos , Cristalino/enzimología , Permeabilidad , Piridazinas/química , Piridazinas/farmacología , Ratas , Nervio Ciático/efectos de los fármacos , Nervio Ciático/enzimología , Sorbitol/sangre , Relación Estructura-Actividad , Sulfonas/química , Sulfonas/farmacologíaRESUMEN
Acetyl-CoA carboxylase (ACC) catalyzes the rate-determining step in de novo lipogenesis and plays a crucial role in the regulation of fatty acid oxidation. Alterations in lipid metabolism are believed to contribute to insulin resistance; thus inhibition of ACC offers a promising option for intervention in type 2 diabetes mellitus. Herein we disclose a series of ACC inhibitors based on a spirocyclic pyrazololactam core. The lactam series has improved chemical and metabolic stability relative to our previously reported pyrazoloketone series, while retaining potent inhibition of ACC1 and ACC2. Optimization of the pyrazole and amide substituents led to quinoline amide 21, which was advanced to preclinical development.
Asunto(s)
Acetil-CoA Carboxilasa/antagonistas & inhibidores , Lactamas/farmacología , Animales , Área Bajo la Curva , Lactamas/química , Espectroscopía de Resonancia MagnéticaRESUMEN
Two new templates, (R) 2-hydroxyethyl-pyridine and (R) 2-hydroxyethyl-triazine, were used to design novel sorbitol dehydrogenase inhibitors (SDIs). The design concept included spawning of these templates to function as effective ligands to the catalytic zinc within the enzyme through incorporation of optimally substituted piperazino-triazine side chains so as to accommodate the active site in the enzyme for efficient binding. This strategy resulted in orally active SDIs, which penetrate key tissues, for example, sciatic nerve of chronically diabetic rats. The latter template led to the design of the title inhibitor, 33, which normalized the elevated sciatic nerve fructose by 96% at an oral dose of 10mg/kg.
Asunto(s)
Inhibidores Enzimáticos/síntesis química , Etanol/análogos & derivados , L-Iditol 2-Deshidrogenasa/antagonistas & inhibidores , Piperazinas/síntesis química , Triazinas/síntesis química , Administración Oral , Animales , Catálisis , Diabetes Mellitus Experimental/metabolismo , Diseño de Fármacos , Inhibidores Enzimáticos/farmacología , Fructosa/metabolismo , Humanos , L-Iditol 2-Deshidrogenasa/metabolismo , Piperazinas/farmacología , Ratas , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Relación Estructura-Actividad , Triazinas/farmacología , Zinc/químicaRESUMEN
SAR studies on the stereoisomers of CP-470,711 suggested that in vivo epimerization was taking place in rats. Further metabolism studies revealed that no epimerization was occurring in dogs, and that no epimerization was expected in humans. A mechanism for the in vivo epimerization is proposed involving an oxidation-reduction pathway of the secondary benzylic alcohol, in contrast to an acid/base-promoted epimerization of the same center during chemical synthesis.